Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia | Synapse
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Key Points
The analysis aims to compare the clinical efficacy and cost-effectiveness of zanubrutinib and acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
Conducted a number needed to treat (NNT) analysis.
Compared treatment outcomes and costs between zanubrutinib and acalabrutinib.
Focused on relapsed/refractory chronic lymphocytic leukemia patients.
Zanubrutinib demonstrated more favorable clinical outcomes compared to acalabrutinib.
Zanubrutinib was associated with lower costs in the population studied.
High-risk CLL patients benefitted significantly from zanubrutinib.
Abstract
The NNT analysis demonstrates that treatment with zanubrutinib versus acalabrutinib is associated with more favorable clinical and economic outcomes in R/R CLL, especially in high-risk CLL patients.